Background. The use of machine perfusion (MP) in kidney transplantation lowers delayed graft function (DGF) and improves 1-year graft survival in some, but not all, grafts. These associations have not been explored in grafts stratified by the Kidney Donor Profile index (KDPI). Methods. We analyzed 78 207 deceased-donor recipients using the Scientific Registry of Transplant Recipients data from 2006 to 2013. The cohort was stratified using the standard criteria donor/expanded criteria donor (ECD)/donation after cardiac death (DCD)/donation after brain death (DBD) classification and the KDPI scores. In each subgroup, MP use was compared with cold storage. Results. The overall DGF rate was 25.4% and MP use was associated with significantly lower DGF in all but the ECD-DCD donor subgroup. Using the donor source classification, the use of MP did not decrease death-censored graft failure (DCGF), except in the ECD-DCD subgroup from 0 to 1 year {adjusted hazard ratio [aHR] 0.56 [95% confidence interval (CI) 0.32-0.98]}. In the ECD-DBD subgroup, higher DCGF from 1 to 5 years was noted [aHR 1.15 (95% CI 1.01-1.31)]. Also, MP did not lower all-cause graft failure except in the ECD-DCD subgroup from 0 to 1 year [aHR ¼ 0.59 (95% CI 0.38-0.91)]. Using the KDPI classification, MP did not lower DCGF or all-cause graft failure, but in the 70 subgroup, higher DCGF [aHR 1.16 (95% CI 1.05-1.27)] and higher all-cause graft failure [aHR 1.10 (95% CI 1.02-1.18)] was noted. Lastly, MP was not associated with mortality in any subgroup. Conclusions. Overall, MP did not lower DCGF. Neither classification better risk-stratified kidneys that have superior graft survival with MP. We question their widespread use in all allografts as an ideal approach to organ preservation.
I N T R O D U C T I O N
Machine perfusion (MP) is an organ preservation technique that entails a continuous or pulsatile circulation of perfusate through the graft [1] . When compared with cold storage (CS), MP use has been demonstrated to have several benefits. It decreases apoptosis, markers of ischemia reperfusion injury, pro-inflammatory cytokine expression and interstitial fibrosis and tubular atrophy in human and animal models [1] [2] [3] [4] [5] [6] [7] . Thus it is postulated that MP improves graft outcomes.
Indeed, in the field of kidney transplantation (KT), multiple meta-analyses, systematic reviews, registry data analyses and randomized trials have reported a reduction in delayed graft function (DGF) with MP use across all donor subgroups: standard criteria donor (SCD), donation after brain death (DBD), expanded criteria donor (ECD) and donation after cardiac death (DCD) [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . The Eurotransplant trial, which aimed to study the clinical benefits of MP, assigned one kidney from 336 consecutive deceased donors to MP and the other to CS [22] . MP use significantly lowered the rate of DGF [22] . Hence the use of MP has increased significantly: 12.9% of grafts underwent MP from 1994 to 2003 [15] , but from 2005 to 2011 this increased to 37.8% [20] . This increase was of most significance in kidney allografts that are traditionally considered to be at high risk for DGF, i.e. grafts from ECD and DCD donors [8, 15, 20] . From 2005 to 2011, 56% of the ECD kidneys and 75% of the DCD kidneys underwent MP [20] .
However, MP use in these high-risk kidneys has not been consistently shown to improve graft survival [9-11, 13-18, 20, 21, 25-28] . In the Eurotransplant trial, at 3 years, MP use was associated with superior graft outcomes in recipients of allografts from ECD but not DCD donors [28] . A systematic review of seven studies, involving 11 090 grafts from ECD, reported superior 1-year graft survival with MP use [13] . On the other hand, a registry analysis of 4618 recipients of ECD grafts reported similar 3-year graft survival with MP use [16] . In a systematic review and meta-analysis involving DCD donors only, MP use was not associated with improved 1-year graft survival in the recipient [10] . Lastly, the use of MP in kidney allografts from DCD donors younger than 50 years was associated with a 35% increased risk for graft loss [29] .
The United Network of Organ Sharing (UNOS) is now using a new allocation policy that risk-stratifies deceased donors using the Kidney Donor Profile Index (KDPI) [30] . Using 10 donor factors that are associated with all-cause allograft survival, a numerical score is assigned to each donor [31] . The higher the number, the higher the expected risk of graft failure [31] . This score is thought to provide a more robust evaluation of deceased donor quality. Since the adoption of this allocation policy, no study has analyzed the benefit of MP use in grafts that have a high KDPI score. Hence the objectives of our study were to analyze and compare the association of MP use and CS on graft outcomes, stratified by KDPI scores and donor source, i.e. the SCD/ECD/DCD/DBD classification. The graft outcomes of interest were DGF, death-censored graft failure (DCGF), allcause graft failure and mortality. We also wanted to analyze whether KDPI scores help risk-stratify kidney allografts that have superior graft outcomes with the use of MP when compared with the donor source classification.
M A T E R I A L S A N D M E T H O D S

Data source
This study used data from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donors, wait-listed candidates and transplant recipients in the USA, submitted by the members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services Administration, US Department of Health and Human Services, provides oversight to the activities of the OPTN and SRTR contractors.
Study population
All adult (!18 years) deceased donor KT recipients in the USA between 2006 and 2013 (n ¼ 78 207) were included in this analysis. For 10 grafts, the exact KDPI score could not be calculated due to missing variables [donor serum creatinine (SCr)] and these were excluded from the analysis.
Definitions
ECDs included all brain-dead donors ! 60 years of age and donors 50-59 years of age with two or more of the following comorbidities: (i) history of hypertension, (ii) death resulting from cerebrovascular accident and (iii) terminal SCr !1.5 mg/dL. SCD included all non-ECDs. The DCD subgroup was identified on the basis of the UNOS designation of non-heart-beating donation as reported by SRTR. We classified the donors into four categories based on the sequence and mode of death: SCD and DBD, SCD and DCD, ECD and DBD and ECD and DCD [32] .
The KDPI score was calculated from donor variables including age, race, diabetes, hypertension, SCr, height, weight, hepatitis C seropositivity and cause of death using the method described by the OPTN [33] and categorized as 70, 71-80, 81-85, 86-90 or 91-100. The KDPI scores were calculated retrospectively and stratified more granularly based on current discard patterns that tend to increase dramatically for kidneys with KDPI >70 [34] . DGF was defined as the need for dialysis within the first week posttransplant. Primary nonfunction (PNF) was defined as failure of the transplanted kidney to function within the first 3 months posttransplant.
Graft outcomes
After stratifying by donor source and KDPI score, outcomes of interest were compared separately for grafts that underwent MP versus CS in each subgroup. The outcomes of interest were DGF, DCGF, all-cause graft failure and mortality. DGF was modeled using logistic regression. For model selection, we used the SRTR standard model, which was built using the least absolute shrinkage and selection operator technique [35] . We adjusted for the following donor and graft variables: cold ischemia time, race, age, cause of death, diabetes, hypertension, SCr, human leukocyte antigen mismatch, share type and donor/ recipient weight ratio. Recipient variables included age, gender, race, body mass index, primary diagnosis, hepatitis C virus, previous transplant, renal replacement therapy time and insurance type. We also adjusted for calendar year and center-specific time to transplant. PNF kidneys were excluded when analyzing the impact of MP use on DGF. Unadjusted DCGF for MP use versus CS was estimated using the Kaplan-Meier method for each donor subgroup. To explore for an association between MP use and DCGF, all-cause graft failure and mortality, we used the Cox models. We adjusted for the donor, recipient and graft variables, as mentioned above.
Center-level logistic model
Lastly we explored whether center-level characteristics influenced the magnitude of effect of MP use and graft outcomes above and beyond the above-listed characteristics. For this analysis we looked at two graft outcomes: DGF and 1-year graft survival. We fit a hierarchical model that incorporated plausible center-level characteristics that were measured in or could be calculated from the SRTR data. We excluded ECD-DCD patients from this analysis given the small numbers at risk.
Statistical analysis
Continuous variables were described using means, medians and frequencies. Between-group comparisons were made using the Student's t-test, chi-squared test or Fisher's exact test, as appropriate. Missing values were handled by multiple imputations. All analyses were performed using Stata 12.0/MP for Linux (StataCorp, College Station, TX, USA).
R E S U L T S
Study population
A total of 78 207 adult, deceased-donor KT recipients met the inclusion criteria and were stratified by donor source and KDPI scores: SCD-DBD (n ¼ 54 458), SCD-DCD (n ¼ 10 082), ECD-DBD (n ¼ 12 804), ECD-DCD (n ¼ 863) and KDPI 70 (n ¼ 59 098), 71-80 (n ¼ 7707), 81-85 (n ¼ 3643), 86-90 (n ¼ 3120) and 91-100 (n ¼ 4629).
Baseline characteristics
When compared with SCD-DBD kidneys (26.7%), a higher percentage of SCD-DCD, ECD-DBD and ECD-DCD kidneys underwent MP: 72.4%, 53.2% and 87.6%, respectively (Table 1) . When compared with kidney allografts with KDPI scores 70 (33.1%), a higher percentage of grafts with KDPI scores >70 underwent MP: 46.7%, 52.8%, 52.5% and 56.9% of grafts with KDPI scores 71-80, 81-85, 86-90 and 91-100, respectively ( Table 2 ). The median donor SCr was 0.9 mg/dL in all subgroups.
DGF
The overall rate of DGF in our cohort was 25.4%. When stratified by donor source, DGF rates were as follows: 21.4% in the SCD-DBD, 39.7% in the SCD-DCD, 29.2% in the ECD-DBD and 53.8% in the ECD-DCD subgroups. When (Table 4) .
We then analyzed these outcomes using the five subgroups stratified by KDPI scores. From 0 to 1 year and 1 to 5 years, use of MP was not associated with DCGF except in the 70 subgroup. In this subgroup, from 0 to 1 year, use of MP was associated with a 16% higher DCGF [aHR 1.16 (95% CI 1.05-1.27), P < 0.01] and a 10% higher all-cause graft failure [aHR 1.10 (95% CI 1.02-1.18), P ¼ 0.01]. In the other subgroups, stratified by KDPI scores, use of MP was not associated with all-cause graft failure. Lastly, MP use was not associated with mortality in any of the five subgroups over the entire study period (Table 5) .
Center-level heterogeneity
MP use varied from 0 to 100%. After excluding PNF grafts and centers that did not use MP, the aOR for DGF varied from 0.41 to 0.90 across various centers (Figure 1) . A likelihood ratio test yielded P < 0.01 and the interclass correlation coefficient was 11%. The aOR for 1-year graft failure varied from 0.81 to 1.28 across various centers (Figure 2) . A likelihood ratio test yielded P ¼ 0.24 and the interclass correlation coefficient was 2%.
D I S C U S S I O N
In this national study of nearly 80 000 KT recipients, MP when compared with CS was associated with lower DGF rates. Despite this, MP use did not impact graft outcomes beyond 1 year. In fact, MP use was associated with a 16% higher DCGF and a 10% higher all-cause graft failure in the KDPI 70 subgroup in the first year. Also, 15% higher DCGF was noted from 1 to 5 years in the ECD-DBD subgroup. In the ECD-DCD subgroup, MP use did not influence DGF rates; however, lower DCGF and all-cause graft failure were noted in the first year, but not beyond. While the use of MP varied across transplant centers, the effect of MP on DGF and 1-year graft survival did not seem to be different. Hence, varied center-level practices do not explain our findings. Lastly, neither the SCD/ECD/DCD/ DBD classification nor the KDPI scoring help risk-stratify grafts that have superior long-term survival with the use of MP.
Most studies have shown a reduction in DGF rates with MP use, with an OR ranging from 0.43 to 0.64 [10, 14, 16, 17, [20] [21] [22] [23] . It is unclear whether the decrease in DGF with MP use is because of an intrinsic effect of MP or due to other factors FIGURE 1: Center-level variation: hierarchical multivariate logistic regression models were used to derive the center-specific impact of MP on DGF. associated with the logistics of MP, such as discarding of grafts based on pump parameters [19] . In our study, MP use was associated with a decreased rate of DGF, with an aOR that ranged from 0.53 to 0.62 in all subgroups except in the ECD-DCD subgroup, where it did not reach statistical significance. Only one randomized trial of 45 DCD donors, which assigned one kidney to MP and the other to CS, reported no association between MP use and DGF [36] . We postulate this to be due to the low numbers at risk. Also, this subgroup is at a much higher risk for confounding by indication bias and higher discard rates based on pump parameters, none of which could be captured in our analysis or were mentioned in the trial.
With respect to DCGF and all-cause graft failure, overall there was no major benefit of MP use from 0 to 1 or 1 to 5 years. The following studies have shown no association with MP use and 1-year graft survival when compared with CS: a propensity-matched cohort of 26 586 kidney allografts [20] , a propensity-matched cohort of 17 858 SCD allografts only [21] , a metaanalysis of 11 randomized controlled trials and 7 prospective but nonrandomized cohorts [24] , 2 separate meta-analyses involving DCD allografts only [10, 14] , a systematic review of 7 randomized controlled trials [11] , a registry analysis of 4618 ECD allografts only [16] , another registry analysis of 7397 of ECD allografts only [17] and a randomized controlled trial of 82 DCD kidney pairs [23] . On the other hand, a meta-analysis of 11 090 ECD allografts only reported that 1-year graft survival was significantly improved with MP use, with an OR of 1.12 [13] . The difference in the interpretation of this meta-analysis, compared with the others, can be explained by studies included in the analysis, the weight assigned to each study and that the statistical analysis utilized survival ratios and not HRs. Also, in the Eurotransplant trial, overall 3-year graft survival was better with MP use, with an HR for graft failure was 0.60 [28] . This could be due to the unified practice in this randomized controlled trial versus the variable practices pertaining to MP use across the USA included in our cohort. Lastly, a registry analysis of deceased donor KT from 1994 to 2003 reported that MP use was associated with a superior death-censored graft survival (aHR 0.88) [15] . The difference between this and our results might be due to an era effect that had a lower utilization of ECD and DCD kidney allografts and also that MP use was much less prevalent in those years.
Increased graft failure in some subgroups is an interesting finding. Belzer et al. [37] has alluded to cellular swelling during MP, principally via fat emboli. In dog heart models, MP was associated with better systolic function; however, it led to more edema and impaired diastolic function [38] . In rat liver models, hepatocytes had better viability and function after MP, however, endothelial cell damage was also described [39] . Mechanical and biological effects induced by shear stress during MP may exacerbate the endothelial cell injury and we postulate that some kidneys might be more susceptible to this.
In our analysis, although the use of MP decreased rates of DGF, this reduction does not seem to translate into improved graft survival. This finding is reported in other settings as well. In DCD kidneys, the increased incidence of DGF does not worsen long-term graft survival [29] . Also, as per some recent reports, prolonged cold ischemia time causing DGF does not have deleterious long-term consequences [40, 41] . This could be because DGF has a complex and perhaps a diverse pathophysiology. Additionally, there is a need to better capture the duration of DGF and the number of dialysis treatments actually administered to each KT recipient.
Our study has the following limitations. We could not capture MP-related center-level practices such as immediate MP versus CS followed by MP, flow-based versus pressure-based systems and continuous versus pulsatile flow. Some of these factors may not be adequately accounted for despite the adjustment for numerous measurable confounders in this analysis. However, by studying center-level heterogeneity we hope to have addressed this. Usually marginal kidneys undergo MP; hence this study suffers from confounding by indication bias. We could not account for discarded kidneys and the impact of MP could only be studied for organs that were utilized.
Despite this, our findings are important. First, the new allocation policy using KDPI scores compared with the older policy was shown to result in transplants with more median extra life years for recipients versus wait-list candidates without increasing mortality on the waiting list [31] . However, recent studies are showing some limitations to this allocation policy. KDPI scores, when interpreted in both a binary and continuous manner, were not effective in predicting shortterm cost [42] . We report that KDPI scoring does not riskstratify kidneys that have superior long-term graft survival with the use of MP. We report that centers are more likely to use MP in donors that are traditionally considered 'high risk', i.e. SCD-DCD, ECD-DBD and ECD-DCD kidneys. The KDPI allocation schema was not utilized during our study period, however, we did note higher rates of MP use in the kidneys with KDPI scores >70. Second, this registry analysis from a larger population allows greater external validity in the current era with novel perfusate solutions and technical improvements in the MP apparatus. Lastly, we report that overall MP use is not associated with lower 5-year DCGF, graft failure and mortality.
In conclusion, when compared with CS, MP use lowers DGF rates for most kidney allografts. However, MP use does not seem to benefit kidney transplant outcomes beyond 1 year and is associated with inferior outcomes in those grafts with KDPI 70 from 0 to 1 year. Neither the KDPI scoring nor the SCD/ECD/DCD/DBD classification risk-stratify grafts that have superior long-term survival with the use of MP. We question the widespread use of MP in all deceased-donor KTs as an ideal approach to organ preservation because there is no demonstrable long-term benefit, in particular, in those grafts that are considered 'high risk'. For now, one could argue that MP use should be driven by potential therapeutic options during MP, decreased discard rates, potential reduction in morbidity, length of hospital stay and immediate cost savings due to reduced DGF [15, 17, 43, 44] . Studies demonstrating the clinical superiority and financial feasibility of MP use and perhaps validating a graft-tailored approach to organ preservation are needed. 
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